Screener
Vera Therapeutics VERA Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Vera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Vera Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:33 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212143
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 122,042 | 130,212 |
| Stockholders’ equity | ||
| Class A common stock, $0.001 par value; 500,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 71,730,090 and 71,267,429 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 72 | 71 |
| Additional paid-in capital | 1,381,678 | 1,364,529 |
| Accumulated other comprehensive (loss) income | (156) | 786 |
| Accumulated deficit | (881,897) | (760,865) |
| Total stockholders’ equity | 499,697 | 604,521 |
| Total liabilities and stockholders’ equity | $621,739 | $734,733 |
Item 1. Financial Statements
FAQ
- What is Vera Therapeutics's total equity?
- Vera Therapeutics (VERA) reported total equity of $499.7M in Q1 2026.
- How has Vera Therapeutics's total equity changed year-over-year?
- Vera Therapeutics's total equity decreased by 6.6% year-over-year, from $535M to $499.7M.
- What is the long-term trend for Vera Therapeutics's total equity?
- Over 5 years (2020 to 2025), Vera Therapeutics's total equity has grown at a 46.6% compound annual growth rate (CAGR), from -$89.35M to $604.52M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Vera Therapeutics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude